<DOC>
	<DOCNO>NCT02243709</DOCNO>
	<brief_summary>The goal study determine , stress , alcohol drinking reduce use mifepristone</brief_summary>
	<brief_title>Mifepristone Prevention Relapses Alcohol Drinking</brief_title>
	<detailed_description />
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<mesh_term>Yohimbine</mesh_term>
	<criteria>Male female , 21 65 year age Females must postmenopausal least one year surgically sterile ( proven medical record ) Meet criterion Alcohol Use Disorders ( AUD ) DSM5 diagnosis Meet drinking criterion ( ≥3 drinks/day men ; ≥2 drink /day woman ) Must good health confirm medical history , physical examination , ECG , lab test Participants must willing take oral medication adhere study procedure Breath alcohol ( BrAC ) = 0.00 visit Be able understand inform consent questionnaire English 8th grade level Individuals express interest treatment alcoholism Premenopausal woman Participants significant alcohol withdrawal symptom , define CIWAAr score ≥7 A repeat positive urine drug screen baseline illegal substance except marijuana . Individuals diagnose current `` severe '' Substance Use Disorder ( SUD ) diagnosis , alcohol nicotine Meet DSM5 criterion diagnosis schizophrenia , bipolar disorder , psychoses An active illness within past six month screen visit meet DSM5 criterion diagnosis Major Depressive Disorder ( MDD ) Anxiety Disorder , history attempt suicide Clinically significant medical abnormality : unstable hypertension , clinically significant abnormal ECG , bilirubin &gt; 150 % upper normal limit , ALT/AST &gt; 300 % UNL , creatinine clearance ≤60 dl/min Current use psychotropic medication may effect alcohol consumption Current use medication involve metabolism alcohol aldehyde dehydrogenase ( ALDH ) , alcohol dehydrogenase ( ADH ) CYP2E1 : Cefamandole , Cefotetan , Sulfamethoxazole , Nitroglycerin , Chlorpropamide , Glyburide . Current use medication ( CYP3A4 inhibitor substrate ) may interact mifepristone : cyclosporine , fentanyl , heparin , escitalopram , lovastatin , simvastatin , warfarin Current use medication ( CYP2D6 inhibitor substrate ) may interact yohimbine : amitriptyline , doxepin , nortriptyline , venlafaxine Medical contraindication use mifepristone yohimbine A history adverse reaction hypersensitivity mifepristone yohimbine History suicide History seizure disorder Hypokalemia ( low potassium level ) &lt; 3.5mEq/L Participated behavioral and/or pharmacological study within minimum past 30 day Neuroendocrine disorder Taking corticosteroid Bleeding disorder Preexisting QT prolongation ECG History porphyria ( Mifepristone progesterone receptor antagonist inducer CYP450 therefore may ability precipitate exacerbate attack acute porphyria ) Not willing engage protect sex ( condom ) . This risk include woman men . Mifepristone long halflife ( t1/2 = 18 hr ) three main metabolite retain considerable affinity toward human progesterone glucocorticoid receptor , serum level similar parent mifepristone study presence mifepristone metabolites semen</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Stress , alcohol craving , alcohol use disorder</keyword>
</DOC>